Mantis Biotech Develops Digital Twins to Advance Medical Data Access
Mantis Biotech is developing digital twins—AI-based virtual models of humans—to address the challenge of data scarcity in medical research and treatment. The company's technology aims to improve access to reliable, high-quality patient data for healthcare innovation.
Mantis Biotech is focusing on the development of 'digital twins'—detailed, AI-powered virtual representations of individual humans—with the goal of tackling the medical sector’s persistent data availability problem. Medical researchers and technology developers often face barriers in accessing high-quality, diverse patient data due to privacy rules and fragmented health databases. This shortage hampers the advancement of personalized medicines and the validation of potential new treatments.
The 'digital twin' approach leverages artificial intelligence to simulate individual patient characteristics, responses to therapies, and disease progression. By building virtual models that replicate human biology and health outcomes, these twins can stand in for real patient data where access or volume is limited. Mantis Biotech’s technology combines multiple data sources, including anonymized clinical records and molecular data, to create robust, research-valid virtual patients.
Digital twins have emerged as a promising tool in medical innovation. Traditionally, clinical research has relied on real-world data from limited and often non-representative patient populations. AI-generated digital twins offer a scalable alternative, enabling simulations on thousands of virtually constructed patients to better illustrate drug responses and predict adverse outcomes.
Despite the promise, experts note that digital twins must be rigorously validated to ensure they accurately mirror the complexities of human biology and react as expected to new treatments or environmental factors. Questions remain around regulatory acceptance and how such technology can be integrated into decision-making in drug development and personalized medicine.
If successful, Mantis Biotech’s digital twin models could help researchers and clinicians overcome critical bottlenecks in the development pipeline for new therapies. The approach also holds potential for improving clinical trial design, supporting rare disease research, and making precision medicine more widely accessible by supplementing gaps in available datasets.
The rise of AI-assisted tools like digital twins reflects a broader trend in healthcare digital transformation, where artificial intelligence increasingly underpins data-driven innovation. While adoption is still early stage and real-world impact remains to be seen, the sector continues to attract significant investment.
Related Posts
Agentic AI Aims to Address Global Healthcare Workforce Shortages
Agentic AI systems are being used to reduce administrative burdens and streamline workflows in healthcare amid growing global staffing shortages. Early adopters, such as Hospital for Special Surgery in New York, report improved efficiency and patient access through AI-driven automation and triage. Widespread adoption relies on robust safeguards, data integration, and oversight to ensure safe, effective implementation.
Researchers Make Mice Transparent to Study Obesity’s Impact on Nerves
Scientists have developed a method to render mice transparent, enabling direct observation of how obesity affects nerve cells. This advancement could pave the way for improved understanding and treatment of obesity-related health issues.
Majority of CEOs Predict Job Losses from AI Within Two Years
A global survey indicates 99% of CEOs expect artificial intelligence to reduce jobs within two years, marking a significant shift in workplace expectations. The findings highlight growing executive confidence in AI technologies and their likely impact on employment.